<DOC>
	<DOCNO>NCT01387906</DOCNO>
	<brief_summary>The primary purpose study assess efficacy safety Latisse ( bimatoprost .03 % ophthalmic solution ) apply lateral medial eyebrow . The primary outcome increase overall eyebrow prominence measure least 1-grade increase Global Eyebrow Assessment ( GEyA ) scale , baseline end treatment day 270 period .</brief_summary>
	<brief_title>Latisse ( Bimatoprost .03 % Opthalmic Solution ) Treatment Hypotrichosis Eyebrows : Latisse Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Hypotrichosis</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Outpatient , female/male subject race , 1875 year age . Subjects childbearing potential must negative urine pregnancy test result Baseline practice reliable method contraception throughout study Patients hypotrichosis ( thin ) eyebrows GEyA score 1 2 . Patient agree abstain treatment eyebrow include : waxing , plucking , thread , laser hair removal , and/or bleaching ( exclude glabella region ) . Able understand requirement study sign Informed Consent/HIPAA Authorization form . Written informed consent write authorization use release health research information obtain . Willing complete require study visit , procedure , evaluation include photography . Subjects pregnant ( positive urine pregnancy test ) , plan become pregnant , breastfeeding , childbearing potential practicing reliable method birth control . Patients uncontrolled systemic disease Patient know disease abnormality eyebrows include eczema seborrheic dermatitis Patients know suspected trichotillomania disorder Patients history glaucoma and/or increase ocular pressure Patients currently use IOPlowering prostaglandin analog ( include Lumigan ) Patients know hypersensitivity bimatoprost ingredient Latisse Previous cosmetic surgery upper face ( e.g. , periorbital surgery , brow lift , eyelid eyebrow surgery , etc. ) . Patients permanent eye and/or eyebrow makeup Any eyebrow tint dye application within 2 month prior study entry Any plan facial cosmetic procedure would interfere evaluation eyebrows Participation another investigational drug device study within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>mild</keyword>
	<keyword>moderate</keyword>
</DOC>